SCHEMBL20132906

SCHEMBL20132906

CC(C)(C)OC(=O)N1CC(OCCCOCCCOCc2ccccc2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.47
PRMT5 O14744 2/20 0.45
WDR77 Q9BQA1 2/20 0.45
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
STS P08842 1/20 0.44
GPR119 Q8TDV5 2/20 0.43
USP30 Q70CQ3 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
NAMPT P43490 1/20 0.42
RORC P51449 1/20 0.41
TEAD3 Q99594 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
TACR1 P25103 1/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129209 0.99 L3MBTL1 (0.47) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL22906672 0.97 L3MBTL1 (0.51) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL28959331 0.97 L3MBTL1 (0.50) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL20132907 0.92 PRMT5 (0.45) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL2387673 0.92 PRMT5 (0.47) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL30750608 0.89 STS (0.50) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL31303428 0.89 STS (0.52) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL31618716 0.88 PRMT5 (0.49) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL20133355 0.88 STS (0.51) L3MBTL1PRMT5WDR77JAK2JAK1
SCHEMBL20133161 0.87 STS (0.50) L3MBTL1PRMT5WDR77JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN L3MBTL1 1412/4885PRMT5 584/4885WDR77 1631/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 L3MBTL1 1300/4885PRMT5 547/4885WDR77 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.